Vote Scores
Filings read through

Spyre Therapeutics, Inc.: how funds voted at the meeting of 13 May 2024

Ticker
SYRE
Meeting
Season
year to 30 June 2024
Filers reporting
105
Ballot items
5

105 filers on Form N-PX reported votes at the Spyre Therapeutics, Inc. meeting of 13 May 2024. The records fall into 5 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

This meeting is in the year to 30 June 2024. The latest season on file is the year to 30 June 2026. The page of Spyre Therapeutics, Inc. has the latest meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2024. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    2 nominees. 48.0% of the reported votes are for. 11 filers withheld from or voted against at least one nominee.

    102 vote records from 30 filers. 9 of the 30 filers that marked the item voted against management.

    • Positions of 14 fund families
    • For 12
    • Abstain or withhold 1
    • Split or no vote 1
    • Against management 1
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    148 vote records from 105 filers. 66 of the 97 filers that marked the item voted against management. 8 filers gave no management mark.

    • Positions of 19 fund families
    • For 6
    • Against 12
    • Split or no vote 1
    • Against management 12
  3. Item 3: Audit-related items (auditor ratification)

    51 vote records from 30 filers. 0 of the 30 filers that marked the item voted against management.

    • Positions of 14 fund families
    • For 14
  4. Item 4: CAPITAL STRUCTURE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    102 vote records from 30 filers. 1 of the 30 filers that marked the item voted against management.

    • Positions of 14 fund families
    • For 13
    • Against 1
    • Against management 1
  5. Item 5: CORPORATE GOVERNANCE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    102 vote records from 30 filers. 0 of the 30 filers that marked the item voted against management.

    • Positions of 14 fund families
    • For 5
    • Split or no vote 9

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Spyre Therapeutics, Inc., meeting of 13 May 2024Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Auditor
American CenturyForFor
BlackRock and iSharesAgainst, against managementFor
BNY MellonAgainst, against managementFor
Charles SchwabAgainst, against managementFor
EquitableForFor
FidelityAgainst, against managementFor
Franklin TempletonAgainst, against managementFor
Goldman SachsSplitNo report
Guggenheim and RydexAgainst, against managementFor
InvescoAgainst, against managementNo report
Janus HendersonAgainst, against managementNo report
John Hancock and ManulifeForFor
MassMutualForFor
NationwideAgainst, against managementFor
Northern Trust and FlexSharesAgainst, against managementNo report
PIMCOAgainst, against managementNo report
State Street and SPDRForFor
T. Rowe PriceForFor
VanguardAgainst, against managementFor

Questions

How many filers reported votes at the Spyre Therapeutics, Inc. meeting?
105 Form N-PX filers reported votes at the meeting of 13 May 2024. On say-on-pay, 66 of 97 filers that marked the item voted against management (68.0%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Spyre Therapeutics, Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Spyre Therapeutics, Inc. with a meeting date within three days of 13 May 2024. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .